Efficacy and Safety of Aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Efficacy and Safety of Aficamten in the First Cohort of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Completing 48-Week Follow-up: Findings From FOREST-HCM

Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Aficamten and its Metabolites

Drug–Drug Interaction Study to Evaluate the Effect of Strong CYP3A Inhibition and P450 Induction on the Pharmacokinetics of Aficamten and the Effect of Aficamten on P-Glycoprotein in Healthy Participants

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of Aficamten in Healthy Chinese Participants: a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study

COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial

Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3

The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF

Disposition and Metabolism of the Cardiac Myosin Inhibitor Aficamten in Humans